---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-106395"
form_type: "8-K"
ticker: "ADIL"
cik: "0001513525"
company_name: "ADIAL PHARMACEUTICALS, INC."
filed_at: "2026-10-02T20:16:12+00:00"
generated_at: "2026-10-12T14:37:15.685295+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Adial Pharmaceuticals adjourns 2026 annual meeting again over pending Nasdaq listing approval

## Summary
- Adial adjourned votes on Proposals 3, 4, 5 and 6 at its 2026 Annual Meeting because Nasdaq had not approved its Initial Listing Application.
- The reconvened Oct. 1, 2026 meeting was further adjourned; polls remain open and the meeting will reconvene Oct. 15, 2026 at 8:30 a.m. ET.
- The record date for the 2026 Annual Meeting remains Aug. 17, 2026, and stockholders who already voted on Proposals 3-6 need not act unless changing their vote.
- Proposals 1, 2, 7, 8, 9, 10, 11 and 12 were voted on at the Sept. 17, 2026 meeting; the definitive proxy statement was filed Aug. 24, 2026.

## SEC filing metadata
- accession: 0001213900-26-106395
- form_type: 8-K
- ticker: ADIL
- cik: 0001513525
- company_name: ADIAL PHARMACEUTICALS, INC.
- filed_at: 2026-10-02T20:16:12+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1513525/000121390026106395/0001213900-26-106395-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1513525/000121390026106395/ea0307576-8k_adial.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-106395
- JSON: https://secwatch.observer/filing/0001213900-26-106395.json
- Plain text: https://secwatch.observer/filing/0001213900-26-106395.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.